ELISA/assay

Paraoxonase 1 (PON1) ELISA Kit

MBS2022720

24-Strip-Wells

255 USD

ELISA Kit

Paraoxonase 1 (PON1) ELISA Kit

[Paraoxonase 1 (PON1)]

[ESA; PON; Esterase A; Serum paraoxonase/arylesterase 1; Aromatic esterase 1; A-esterase 1; Serum aryldialkylphosphatase 1]

[paraoxonase 1, partial; Serum paraoxonase/arylesterase 1; serum paraoxonase/arylesterase 1; paraoxonase 1; Aromatic esterase 1; A-esterase 1; K-45; Serum aryldialkylphosphatase 1]

[PON1]

[PON1; PON1; ESA; PON; MVCD5; PON; PON 1; A-esterase 1]

PON1_HUMAN

Human

6

This assay has high sensitivity and excellent specificity for detection of podocan. No significant cross-reactivity or interference between podocan and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

Samples: Human Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids. Assay Type: Quantitative Sandwich. Detection Range: 0.312-20ng/mL. Sensitivity: 0.117ng/mL.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level podocan were tested 20 times on one plate, respectively. Intra-Assay: CV<10%. Inter-assay Precision: Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level podocan were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100. Inter-Assay: CV<12%

Metabolic pathway; Endocrinology

Intended Uses: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of podocan in human tissue homogenates, cell lysates, cell culture supernates and other biological fluids. Principle of the Assay: The microplate provided in this kit has been pre-coated with an antibody specific to podocan. Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to podocan. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain podocan, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of podocan in the samples is then determined by comparing the O.D. of the samples to the standard curve.

345894407

AEO20077.1

39,731 Da

Metabolic Pathways (132956); Phase I, Non P450 Pathway (198854)

The enzyme encoded by this gene is an arylesterase that mainly hydrolyzes paroxon to produce p-nitrophenol. Paroxon is an organophosphorus anticholinesterase compound that is produced in vivo by oxidation of the insecticide parathion. Polymorphisms in this gene are a risk factor in coronary artery disease. The gene is found in a cluster of three related paraoxonase genes at 7q21.3. [provided by RefSeq, Oct 2008]

PON1: Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. Genetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new- onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients. Belongs to the paraoxonase family. Protein type: Motility/polarity/chemotaxis; EC 3.1.1.2; Lipid-binding; EC 3.1.8.1; Phosphatase (non-protein); Hydrolase; Secreted; Secreted, signal peptide; EC 3.1.1.81. Chromosomal Location of Human Ortholog: 7q21.3. Cellular Component: extracellular space; intracellular membrane-bound organelle; extracellular region. Molecular Function: protein homodimerization activity; arylesterase activity; phospholipid binding; calcium ion binding; aryldialkylphosphatase activity. Biological Process: response to external stimulus; response to nutrient levels; dephosphorylation; response to toxin; organophosphate catabolic process; positive regulation of transporter activity; carboxylic acid catabolic process; positive regulation of binding; aromatic compound catabolic process; phosphatidylcholine metabolic process. Disease: Microvascular Complications Of Diabetes, Susceptibility To, 5

24-Strip-Wells

255 USD

48-Strip-Wells

455

96-Strip-Wells

610

5x96-Strip-Wells

2470

10x96-Strip-Wells

4445